The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study

Table 1

Patient demographics.

	Early stage breast cancer patients
	Median age at diagnosis	55.5 years (r: 33.5–76.6 years)
Disease stage
(i) I	14 (29.2%)
(ii) II	23 (47.9%)
(iii) III	11 (22.9%)
Receptor status
(i) ER positive	32 (66.7%)
(ii) PR positive	25 (52.1%)
(iii) HER/2 positive	47 (97.9%)
(iv) HER/2 borderline	1 (2.1%)
Node status
(i) Node positive	16 (33.3%)
Cardiac risk factors (median)	1 (r: 0–7)
(i) Obese (BMI > 30)	13 (27.1%)
(ii) Smoker	11 (22.9%)
(iii) Hypertension	10 (20.8%)
(iv) Hypercholesterolemia	2 (4.2%)
(v) Coronary artery disease	1 (2.1%)
(vi) Diabetes	2 (4.2%)